Company
TheraVet SA
Headquarters: Charleroi, Belgium
Employees: 6
CEO: Mr. Enrico Bastianelli M.B.A., M.D., MBA
Market Cap
€4.4 Million
EUR as of Jan. 1, 2024
US$4.9 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET for osseointegration and bone remodelling; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid with anti-inflammatory properties that promotes the effect of active components, as well as acts as a cell colonization supporting tissue regeneration. The company was incorporated in 2017 and is headquartered in Jumet, Belgium.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
TheraVet SA has the following listings and related stock indices.
Stock: Euronext: ALVET wb_incandescent
Stock: Euronext: ALVET wb_incandescent
Stock: FSX: 31A wb_incandescent